Latest on the Corona Virus
Collapse
X
-
Re: Latest on the Corona Virus
It appears that is the spelling on my phone.
Strange tho you understand exactly ( or close enough ) on what I was saying.
Sent from my SM-G960U using TapatalkComment
-
Re: Latest on the Corona Virus
Yes and an anagram of Omicron is Moronic. Just as pandemic is an anagram of Dempanic.Comment
-
Re: Latest on the Corona Virus
Natural immunity better protects against the Delta strain of COVID-19 than a vaccine, according to a study released by the Centers for Disease Control and Prevention (CDC) on Wednesday.Researchers examined COVID-19 cases and hospitalizations from May through November 2021 in California and New York. The research team examined case and hospitalization rates among four cohorts of people: the unvaccinated and previously uninfected, the vaccinated and previously infected, the unvaccinated with a previous COVID-19 diagnosis, and the vaccinated with a previous COVID-19 diagnosis.The study found that the natural immunity obtained through recovering from a bout of COVID-19 gave people a much greater degree of protection against the Delta strain of COVID-19 than receiving a COVID-19 vaccine. The study said:By the week beginning October 3, compared with COVID-19 cases rates among unvaccinated persons without a previous COVID-19 diagnosis, case rates among vaccinated persons without a previous COVID-19 diagnosis were 6.2-fold (California) and 4.5-fold (New York) lower; rates were substantially lower among both groups with previous COVID-19 diagnoses, including 29.0-fold (California) and 14.7-fold lower (New York) among unvaccinated persons with a previous diagnosis, and 32.5-fold (California) and 19.8-fold lower (New York) among vaccinated persons with a previous diagnosis of COVID-19. During the same period, compared with hospitalization rates among unvaccinated persons without a previous COVID-19 diagnosis, hospitalization rates in California followed a similar pattern. These results demonstrate that vaccination protects against COVID-19 and related hospitalization, and that surviving a previous infection protects against a reinfection and related hospitalization. Importantly, infection-derived protection was higher after the Delta variant became predominant, a time when vaccine-induced immunity for many persons declined because of immune evasion and immunologic waning (2,5,6).The researchers urged caution in drawing conclusions from the study, noting that the vaccine afforded people better protection from COVID-19 variants prior to Delta. The researchers said that the degree of immunity offered by previous infection and by the vaccine is likely to change with the spread of new variants, such as Omicron. The researchers still pushed vaccines as “the safest strategy” for combating COVID-19.“Although the epidemiology of COVID-19 might change as new variants emerge, vaccination remains the safest strategy for averting future SARS-CoV-2 infections, hospitalizations, long-term sequelae, and death. Primary vaccination, additional doses, and booster doses are recommended for all eligible persons. Additional future recommendations for vaccine doses might be warranted as the virus and immunity levels change,” the study said.The Biden administration has continued to push COVID-19 vaccines in its rhetoric and through executive action while downplaying and ignoring the protection offered by natural immunity. Earlier this month, the CDC began emphasizing “up to date” vaccinations over “fully vaccinated,” signaling a shift toward emphasizing booster shots in addition to the original vaccine dose.Dr. Marty Makary of Johns Hopkins University slammed the CDC over the move. “Well CDC just did it, as I predicted. They changed their language from ‘Get a booster’ to ‘Are you up to date?’ This manipulation [of] words implies that low-risk people without a booster are out-of-date. Also sets the stage for [frequent] boosters[.] Covid vaccinations are not software.”
Sent from my SM-G960U using TapatalkComment
-
Re: Latest on the Corona Virus
What Happened After Sweden Took A Hands-Off Approach To COVID-19? | The Daily Wire
Sent from my SM-G960U using TapatalkComment
-
Re: Latest on the Corona Virus
CDC Study: Natural Immunity Beats Vax Against Delta Variant | The Daily Wire
Sent from my SM-G960U using TapatalkComment
-
Re: Latest on the Corona Virus
Lawmakers grill Michigan health director over nursing home COVID deaths | Just The News
Sent from my SM-G960U using TapatalkComment
-
Re: Latest on the Corona Virus
Another old drug is being tried vs. Covid-19, and it might actually Help
Tom Avril, The Philadelphia Inquirer - 1/20/2022
In the first few weeks of the pandemic, when physicians were grappling with the unknown like everyone else, psychiatrist Angela Reiersen recalled that an old drug in her field, called fluvoxamine, affected the body in ways that went beyond improving mental health.
In addition to easing symptoms of obsessive-compulsive disorder and depression, the drug also reduced inflammation, which was emerging as a key culprit in severe cases of COVID-19.
Yet fluvoxamine, a 40-year-old drug that costs a fraction of the pricey new treatments for COVID, now looks as if it will actually help.
A larger, follow-up study in Brazil, patients who took the drug were less likely to need emergency care and hospitalization, compared with those who were given a placebo.
And in Canada, a group of scientists advising the province of Ontario recently gave fluvoxamine a conditional thumbs-up.
A cheap drug <----(Well we can't have those!)
That’s the case with fluvoxamine, which costs just $4 wholesale for a 10-day treatment of COVID, said Lenze, a professor of psychiatry at the St. Louis medical school. (In contrast, you have to shell out about $530 for a course of Paxlovid and $700 for molnupiravir, the new antiviral pills from Pfizer and Merck. And another type of COVID treatment, called monoclonal antibodies, costs more than $2,000.)
But the low cost of fluvoxamine comes with a catch. Because the patent expired on the original formulation of the drug long ago,there is little profit in it. No drug companies would throw their muscle behind such an effort, Lenze said. <---WHOOP! THERE IT IS!
“The very thing that makes it so ideal for repurposing — it’s a generic, it’s widely available, it’s cheap — is also what’s in our way,” he said.
Pretty sad to see that even though something Can and Does save lives, they (big pharma) deem it "unprofitable", and as such, they completely disregard it, or claim that it "doesn't help" or "doesn't have enough evidence" so as to pave the way for their "new drug" that costs upwards of 175 times more! WOO HOO......BONUSES FOR THE BIG SHOTS!!! BIG PROFITS!!!
And here I thought it was all about "saving lives"..........well now we can conclude that it's All About Them Benjamins!
What sick and twisted fuckin' scum they are!OmertÃComment
-
Re: Latest on the Corona Virus
Another old drug is being tried vs. Covid-19, and it might actually Help
Tom Avril, The Philadelphia Inquirer - 1/20/2022
In the first few weeks of the pandemic, when physicians were grappling with the unknown like everyone else, psychiatrist Angela Reiersen recalled that an old drug in her field, called fluvoxamine, affected the body in ways that went beyond improving mental health.
In addition to easing symptoms of obsessive-compulsive disorder and depression, the drug also reduced inflammation, which was emerging as a key culprit in severe cases of COVID-19.
Yet fluvoxamine, a 40-year-old drug that costs a fraction of the pricey new treatments for COVID, now looks as if it will actually help.
A larger, follow-up study in Brazil, patients who took the drug were less likely to need emergency care and hospitalization, compared with those who were given a placebo.
And in Canada, a group of scientists advising the province of Ontario recently gave fluvoxamine a conditional thumbs-up.
A cheap drug <----(Well we can't have those!)
which costs just $4 wholesale for a 10-day treatment of COVID, said Lenze, a professor of psychiatry at the St. Louis medical school. (In contrast, you have to shell out about $530 for a course of Paxlovid and $700 for molnupiravir, the new antiviral pills from Pfizer and Merck. And another type of COVID treatment, called monoclonal antibodies, costs more than $2,000.)
But the low cost of fluvoxamine comes with a catch. Because the patent expired on the original formulation of the drug long ago,there is little profit in it. No drug companies would throw their muscle behind such an effort, Lenze said. <---WHOOP! THERE IT IS!
he said.
Pretty sad to see that even though something Can and Does save lives, they (big pharma) deem it "unprofitable", and as such, they completely disregard it, or claim that it "doesn't help" or "doesn't have enough evidence" so as to pave the way for their "new drug" that costs upwards of 175 times more! WOO HOO......BONUSES FOR THE BIG SHOTS!!! BIG PROFITS!!!
And here I thought it was all about "saving lives"..........well now we can conclude that it's All About Them Benjamins!
What sick and twisted fuckin' scum they are!
Sent from my SM-G960U using TapatalkComment
-
Comment
-
Re: Latest on the Corona Virus
GOP Congressman warns vax mandate for truckers will worsen supply chain ‘crisis’ | Just The News
Sent from my SM-G960U using TapatalkComment
-
Re: Latest on the Corona Virus
REPORT: Mask Mandates Causing Over 350% Surge In Childhood Speech Delays.Comment
Comment